B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.